The role of censoring on progression free survival: Oncologist discretion advised
- 1 November 2015
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (16) , 2269-2271
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Five Years of Cancer Drug ApprovalsJAMA Oncology, 2015
- Influence of censoring on conclusions of trials for women with metastatic breast cancerEuropean Journal of Cancer, 2015
- Impact of Informative Censoring on the Kaplan-Meier Estimate of Progression-Free Survival in Phase II Clinical TrialsJournal of Clinical Oncology, 2014
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2Annals of Oncology, 2014
- Missing Data and Censoring in the Analysis of Progression-Free Survival in Oncology Clinical TrialsJournal of Biopharmaceutical Statistics, 2013
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012